NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PMVP

PMV Pharmaceuticals Inc

Jun 30 • 04:00PM ET

1.06

Dollar change -0.01
Percentage change -0.93	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD MRNA BIIB INCY VRTX REGN NBIX ALNY BLUE

| Held by: VTI VXF IWC BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	15.79%	Shs Outstand	51.95M	Perf Week	-0.93%
Market Cap	55.07M	Forward P/E	-	EPS next Y	-1.76	Insider Trans	0.00%	Shs Float	43.75M	Perf Month	18.38%
Enterprise Value	-104.21M	PEG	-	EPS next Q	-0.38	Inst Own	67.72%	Short Float	1.99%	Perf Quarter	-4.50%
Income	-60.88M	P/S	-	EPS this Y	-35.38%	Inst Trans	-7.55%	Short Ratio	3.84	Perf Half Y	-27.89%
Sales	0.00M	P/B	0.34	EPS next Y	-14.04%	ROA	-29.88%	Short Interest	0.87M	Perf YTD	-29.80%
Book/sh	3.08	P/C	0.34	EPS next 5Y	-15.79%	ROE	-32.66%	52W High	1.82 -41.76%	Perf Year	-36.14%
Cash/sh	3.09	P/FCF	-	EPS past 3/5Y	3.88% -14.06%	ROIC	-37.85%	52W Low	0.81 30.86%	Perf 3Y	-91.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.55% 7.19%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	11.20%	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.75	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	16.75	EPS Q/Q	-13.07%	SMA20	0.59%	Beta	1.48	Target Price	10.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	7.57%	Rel Volume	0.29	Prev Close	1.07
Employees	47	LT Debt/Eq	0.00	Earnings	May 09 BMO	SMA200	-19.88%	Avg Volume	226.52K	Price	1.06
IPO	Sep 25, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.72% -	Trades		Volume	66,482	Change	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Upgrade	Oppenheimer	Perform → Outperform	$6
May-13-24	Initiated	Craig Hallum	Buy	$6
Apr-12-24	Initiated	Jefferies	Buy	$5
Dec-27-23	Initiated	Ladenburg Thalmann	Buy	$7
Mar-02-22	Upgrade	Oppenheimer	Perform → Outperform	$30
Sep-22-21	Upgrade	Goldman	Neutral → Buy	$35 → $43
Aug-19-21	Initiated	Oppenheimer	Perform
Aug-02-21	Initiated	Guggenheim	Buy	$56
Jul-29-21	Initiated	H.C. Wainwright	Buy	$63
Oct-20-20	Initiated	Goldman	Neutral	$34
Oct-20-20	Initiated	Evercore ISI	Outperform	$60
Oct-20-20	Initiated	Cowen	Outperform
Oct-20-20	Initiated	BofA Securities	Buy	$42

Show Previous Ratings

May-23-25 04:05PM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
May-09-25 08:00AM	PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-05-25 09:55AM	Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing (Zacks) +6.20%
Mar-03-25 08:00AM	PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-11-25 08:00AM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Nov-07-24 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results (GlobeNewswire) +7.23%
Oct-23-24 08:00AM	PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial (GlobeNewswire) -6.43%
Aug-08-24 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial (GlobeNewswire)
Jun-03-24 09:55AM	Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher (Zacks)
May-30-24 07:00AM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-29-24 07:00AM	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator (GlobeNewswire) -10.45%
May-09-24 01:54PM	PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-27-24 08:00AM	PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors (GlobeNewswire)
Mar-18-24 04:01PM	PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer (GlobeNewswire) -5.11%
10:21AM	Loading…
Mar-01-24 10:21AM	PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results (GuruFocus.com)
Feb-29-24 04:01PM	PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-26-24 08:00AM	PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +7.78%
Jan-18-24 04:01PM	PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway (GlobeNewswire) -5.76% -10.56%
Jan-05-24 04:01PM	PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development (GlobeNewswire) -5.94%
Nov-09-23 09:41AM	PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
08:00AM	PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-16-23 09:35AM	PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.00%
Oct-12-23 12:30PM	PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation (GlobeNewswire) -47.58%
Oct-11-23 12:00PM	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar (GlobeNewswire) -26.01%
Oct-06-23 09:55AM	Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High? (Zacks) +6.62%
Sep-20-23 04:05PM	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +9.62%
Aug-30-23 09:55AM	Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet (Zacks)
Aug-29-23 09:55AM	PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Aug-09-23 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) +27.69%
04:01PM	Loading…
Jun-06-23 04:01PM	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) +7.56%
May-10-23 08:00AM	PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) +8.33%
Apr-14-23 11:51AM	We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-01-23 08:00AM	PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire) -14.15%
Feb-28-23 04:05PM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Dec-08-22 09:55AM	Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect? (Zacks)
Nov-22-22 08:00AM	PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +5.02%
Nov-17-22 06:18PM	15 Most Shorted Stocks Right Now (Insider Monkey)
Nov-08-22 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Nov-05-22 09:39AM	We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-04-22 08:00AM	PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors (GlobeNewswire)
Oct-11-22 12:00PM	PMV Pharmaceuticals, Inc. (PMVP) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-23-22 09:19AM	10 Most Shorted Stocks in September (Insider Monkey)
Aug-09-22 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -8.06%
Jul-19-22 09:26AM	10 Most Shorted Stocks to Watch in July (Insider Monkey) +5.81%
Jul-18-22 10:47AM	PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors (Benzinga) -9.52%
08:00AM	PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors (GlobeNewswire)
Jun-08-22 08:00AM	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.71%
Jun-07-22 12:00PM	PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation (GlobeNewswire) -21.70%
May-29-22 08:26AM	We're Not Very Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate (Simply Wall St.)
May-26-22 05:05PM	PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +16.05%
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds (American City Business Journals)
May-10-22 07:30AM	PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) +9.66%
Apr-27-22 10:30AM	PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-01-22 07:15AM	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights (GlobeNewswire) +5.11%
Feb-28-22 08:00AM	PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-03-22 08:00AM	PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day (GlobeNewswire)
Jan-12-22 12:20PM	Do Hedge Funds Love PMV Pharmaceuticals, Inc. (PMVP)? (Insider Monkey)
Jan-06-22 08:00AM	PMV Pharma Announces Changes to its Board of Directors (GlobeNewswire) -16.31%
Dec-20-21 10:28AM	We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely (Simply Wall St.)
Nov-22-21 08:00AM	PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference (GlobeNewswire)
Nov-12-21 07:15AM	PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-05-21 11:33AM	Pmv Pharmaceuticals Insider Trades $440K In Company Stock (Benzinga)
Sep-27-21 09:26PM	Goldman Sachs: Buy These 2 Stocks Before They Jump 40% (or More) (TipRanks)
Sep-09-21 08:00AM	PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development (GlobeNewswire)
Sep-02-21 08:00AM	PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-21 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-19-21 06:19PM	Where Do Hedge Funds Stand On PMV Pharmaceuticals, Inc. (PMVP)? (Insider Monkey)
Jun-23-21 05:38AM	We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely (Simply Wall St.)
Jun-09-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference (GlobeNewswire)
Jun-03-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference (GlobeNewswire)
May-14-21 08:00AM	PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire) +10.54%
May-05-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference (GlobeNewswire)
Apr-10-21 01:31PM	PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021 (GlobeNewswire)
Apr-06-21 08:00AM	PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum (GlobeNewswire)
Mar-10-21 04:31PM	PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021 (GlobeNewswire) +12.26%
Mar-03-21 04:01PM	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-16-21 08:00AM	PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board (GlobeNewswire) -9.57%
Dec-25-20 03:44AM	We're Not Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn (Simply Wall St.)
Dec-16-20 03:19PM	Is PMVP A Good Stock To Buy Now? (Insider Monkey)
Nov-24-20 05:00PM	PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference (GlobeNewswire) +8.67%
Nov-23-20 08:00AM	PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53 (GlobeNewswire)
Nov-13-20 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights (GlobeNewswire) -5.50%
Oct-13-20 08:00AM	PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation (GlobeNewswire)
Oct-09-20 03:41PM	Janus Henderson and PMV Pharmaceuticals See Activist Action (Barrons.com)
Oct-01-20 11:57AM	Biotech Pulmonx Shares Climb in Trading Debut (Barrons.com)
Sep-29-20 04:05PM	PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.00% -6.58%
Sep-25-20 02:31PM	PMV Pharma Soars 115% as Biotech IPOs Take Off (Barrons.com)
12:37PM	PMV Pharmaceutical's stock nearly doubles in its debut (MarketWatch)
06:16AM	PMV Pharmaceuticals prices IPO at top end of expectations, raises $211.8 million (MarketWatch)
Sep-24-20 08:06PM	PMV Pharma Announces Pricing of Initial Public Offering (GlobeNewswire)

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mack David Henry	President and CEO	Dec 03 '24	Option Exercise	0.53	91,750	48,628	534,210	Jan 22 04:37 PM
Mack David Henry	President and CEO	Jan 03 '25	Option Exercise	0.53	17,709	9,386	551,919	Jan 22 04:37 PM
Jalota Deepika	Chief Development Officer	Sep 11 '24	Sale	1.50	7,218	10,853	118,283	Sep 12 06:00 PM
Carulli Michael	Chief Financial Officer	Sep 11 '24	Sale	1.50	2,891	4,347	88,395	Sep 12 05:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PMVP

PMV Pharmaceuticals Inc

Upgrade your FINVIZ experience